Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle-Reference-Cited by-同舟云学术

Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle

Published:2019-04 Issue: Volume:1 Page:100004
ISSN:2589-9090
Container-title:Journal of Translational Autoimmunity
language:en
Short-container-title:Journal of Translational Autoimmunity

Author:

El Amrani Mohsin^ORCID,Göbel Camiel,Egas Annelies C.,Nierkens Stefan,Hack C. Erik,Huitema Alwin D.R.,van Maarseveen Erik M.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference24 articles.

1. U.S. National Library of Medicines and National Institute of Health;NIH,2018

2. Immunogenicity to biotherapeutics - the role of anti-drug immune complexes;Krishna;Front. Immunol.,2016

3. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy;Chirmule;AAPS J.,2012

4. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations;Shankar;AAPS J.,2014

5. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis;Bartelds;Ann. Rheum. Dis.,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives;Pharmaceutics;2023-05-12

2. Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial;Clinical Drug Investigation;2023-04

3. Comparison of three commercially available ELISA assays for anti-infliximab antibodies;Pathology;2021-06

4. Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases;JAMA;2021-05-04

5. Association of adalimumab trough concentrations and treatment response in patients with juvenile idiopathic arthritis;Rheumatology;2021-04-20